Sign in
Taking people in United StatesPhase 1

Tests OriCAR-017 cell therapy in adults with relapsed or refractory multiple myeloma

Tests OriCAR-017, a CAR-T cell therapy, in adults with relapsed or refractory multiple myeloma.

Key facts

Who runs it
OriCell Therapeutics Co., Ltd.
Where
Atlanta, United StatesSee the site
Trial code
Registry title
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
Status
Recruiting
Phase
Phase 1
People taking part
81 people, planned
Started
3 Apr 2024
Expected to end
12 Apr 2028
Type of study
Interventional
Treatments tested
  • OriCAR-017
Record updated
2 August 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 75 with multiple myeloma that came back or stopped responding to treatment, and who have already had BCMA-directed therapy.

Age
18 to 75 years
Sex
All sexes can join.
Disease stage
Multiple myeloma that has relapsed or does not respond to treatment, shown by M protein in blood or urine, abnormal free light chains, or lesions outside the bone marrow (more than 1 cm (0.4 in) across the short axis). Expected survival of more than 12 weeks.
Earlier treatment
Must have had earlier BCMA-directed therapy (such as teclistamab, BLENREP or BCMA-CAR-T). In the dose-escalation part, at least 3 prior lines of therapy and no response to the last line. Cannot have had an autologous stem cell transplant within 8 weeks, allogeneic stem cell therapy, or Bendamustine within 1 year before screening.
Biomarker or test result
Serum M protein above 10 g/L (IgG type) or above 5 g/L (IgA, IgD, IgE or IgM type); or urine M protein above 200 mg/24 hour; or serum free light chain above 100 mg/L with an abnormal K/λ ratio.

Main reasons for not taking part

  • Pregnant or breastfeeding
  • HIV positive, or active hepatitis B or hepatitis C
  • Current or past involvement of the central nervous system
  • Autoimmune disease that damaged organs or needed immune-suppressing drugs in the past 2 years
  • Uncontrolled active infection

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Capable of giving signed informed consent
  • Subjects aged 18 to 75 years (inclusive) at Screening (signing the ICF)
  • Expected survival period is >12 weeks
  • Diagnosis of MM according to the IMWG criteria (2016 version)
  • One of the following criteria must be met:
  • If immunoglobulin (Ig)G type MM, then serum M protein >10 g/L; if IgA, IgD, IgE or IgM type MM, then serum M protein >5 g/L
  • Urine M protein level >200 mg/24 hour
  • If light chain type MM, then serum free light chain (sFLC) >100 mg/L and K/λ FLC ratio is abnormal
  • Extramedullary lesions (>1 cm for diameter of the short axis)
  • For Phase I (dose-escalation) - Subjects who had received at least 3 prior lines of therapy, had previous exposure to BCMA-Ag+ therapies, and were refractory to the last line of therapy
  • For Phase I (dose-expansion) and Phase II: Subjects with previous exposure to BCMA directed therapies including BCMA bispecific antibody (e.g., teclistamab), BCMA antibody directed conjugate (such as BLENREP), and BCMA-CAR-T (such as CARVYKT1TM)
  • Subjects with adequate hematologic, renal, hepatic, pulmonary and cardiac function
  • Subject and partners willing to take and or use effective contraceptive measures until 2 years post IMP infusion

Who cannot take part

  • Known active or prior history of CNS involvement
  • Subjects who received autologous hematopoietic stem cell transplantation (ASCT) within 8 weeks of Screening Visit or who plan to undergo ASCT during the study
  • Subjects who received allogeneic stem cell therapy
  • Received Bendamustine treatment 1 year prior to Screening Visit
  • Seropositive for history of human immunodeficiency virus Active Hepatitis B infection and or Hepatitis C infection
  • History of autoimmune diseases (such as Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) caused damage to terminal organs or required systemic application of immunosuppressive or other drugs in the past 2 years
  • Presence of uncontrolled active infection
  • Any condition that in the opinion of the Investigator, would interfere with evaluation of the IMP
  • Pregnant or breastfeeding

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

  • Northside HospitalAtlanta, United StatesContact: Melhem SolhTaking people

About the trial

What the trial wants to find out

The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma.

Read full original descriptionShow less

RIGEL Study

The group in the trial

  • OriCAR-017Treatment being tested

    Single OriCAR-017 infusion

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Anti-GPRC5D CAR-T Cell Product (OriCAR-017) in Subjects With Relapsed/Refractory Multiple Myeloma.
Plain-language title
Tests OriCAR-017 cell therapy in adults with relapsed or refractory multiple myelomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06271252, who can take part
Record updated
2 August 2024